Malaria

This Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine…

This study tests a shorter, higher-dose course of primaquine to cure vivax malaria and prevent it from coming back. Current treatments take too long, so a 3-day course could make it easier for patients to complete therapy. The trial involves over 1,000 people aged 5 and older wit…

This phase 2 trial tests a new malaria vaccine (PfSPZ-LARC2) designed to stop the malaria parasite in the liver before it can cause illness. The study involves 300 healthy women of childbearing age in Mali who plan to become pregnant. Participants receive three doses of the vacci…

This phase II trial tests a new malaria vaccine called PvRII/Matrix-M in 36 healthy Thai adults aged 20-55. Half receive the vaccine, half a placebo. After three doses, 24 volunteers will be exposed to the malaria parasite in a controlled setting to see if the vaccine reduces inf…

This study tests whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in 375 adults and adolescents aged 14 to 60. Participants will receive either the standard dose or a half-dose, and researchers will measure their immune response and safety.…

This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can protect against P. vivax malaria, a major cause of recurrent fever and anemia. 72 healthy adults in Colombia will receive either the vaccine or a placebo, then be exposed to infected mosquitoes…

This early-stage trial will test the SUM-101 malaria vaccine in 24 healthy adults in Tanzania who have been exposed to malaria before. Participants will receive three doses of the vaccine or a rabies control shot, then be deliberately infected with a controlled dose of malaria pa…

This early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …

This study tests whether combining tafenoquine with different antimalarial drugs can better prevent P. vivax malaria from coming back. About 300 adults in Thailand with uncomplicated P. vivax infection will receive one of three drug pairs and be monitored for 6 months. The goal i…

This study looks at how much of the malaria drugs primaquine and tafenoquine pass to babies through breast milk. It involves 60 breastfeeding mothers in Papua New Guinea who recently gave birth. The goal is to find a safe way to treat and prevent relapses of vivax malaria in new …

This study looks at whether a malaria drug called tafenoquine interacts with two other common malaria treatments (DHA-piperaquine and artesunate-pyronaridine) in adults with vivax malaria. About 507 participants will receive one of the combinations or a delayed treatment to compa…

This early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…

This study will test the safety and effectiveness of a drug called tafenoquine in 60 children with vivax malaria in Papua New Guinea. Vivax malaria can hide in the liver and come back, so the goal is to find a treatment that clears the infection completely. The children will rece…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This early-stage study tests whether wearable biosensors (like a wristband or earphones) can detect malaria infection before symptoms appear. 32 healthy adults will be exposed to the malaria parasite or a placebo in a controlled setting. Researchers will compare biosensor reading…

This study aims to validate a non-invasive malaria diagnostic tool that detects specific compounds in breath, called volatile organic compounds (VOCs), using a device called TRACE-E. Researchers will collect breath and blood samples from 200 people aged 12 and older with fever in…

This early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …

This study tests whether giving malaria medicine to school-age children can lower malaria cases in the entire community. School children often carry the malaria parasite without symptoms and spread it to others. The trial will involve about 4,800 children in The Gambia and measur…

This study tests a new long-acting injection called MMV371 to see if it is safe and can prevent malaria. About 80 healthy people aged 12 to 50 in Rwanda will get either the study drug or a placebo. Researchers will check if the injection protects against malaria and monitor side …

This pilot study tests whether giving a malaria drug (dihydroartemisinin piperaquine) to household members of pregnant women can help prevent malaria in the mothers. About 300 participants in Uganda will receive either a single dose or monthly doses. The goal is to see if this ap…

This study tests new devices called LASER that release a chemical to repel mosquitoes, comparing them to indoor insecticide spraying and standard prevention (bed nets, vaccines). About 22,800 people in 69 Kenyan villages will take part over two years. Researchers will check malar…

This study in Uganda will test whether giving children both the R21 malaria vaccine and two different malaria prevention medicines works better than the vaccine alone. About 1,290 children will take part. The goal is to see if the combination can reduce malaria cases more effecti…

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This early-stage study will check if a new experimental drug for malaria, called GSK3772701, changes how the body processes other medications. Twenty healthy adults aged 18 to 55 will take both GSK3772701 and a common probe drug called midazolam. The goal is to see if GSK3772701 …

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This early-stage trial will give 24 healthy adults three different malaria drugs—piperaquine, pyronaridine, and artesunate—alone and together to see how they interact. Researchers will measure drug levels in the blood and watch for side effects. The goal is to learn about safety …

This study looks at how different genetic makeups affect the way healthy adults process the malaria prevention drug tafenoquine (ARAKODA). Researchers will measure drug levels in blood and urine over time, along with safety checks. The goal is to better understand how to dose the…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.